Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07497854

A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea

The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Migraine With or Without Aura

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The objective of this study is to determine any problems or questions associated with NURTEC® after marketing, with regard to the following clauses under conditions of general clinical practice, in compliance with the regulation "Re-examination Guideline of New Drugs".

  • Serious adverse event/adverse drug reaction
  • Unexpected adverse event/adverse drug reaction that have not been reflected in the approved drug label.
  • Known adverse drug reaction
  • Non-serious adverse drug reaction
  • Other safety and effectiveness information As required for any new medication approved by Ministry of Food and Drug Safety (MFDS), information on safety and effectiveness of new medication should be researched on certain number of subjects taking the drug in the setting of routine practice during the initial 6 years after the approval of new drug. This reserach shall begin after approval of marketing in Korea by MFDS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  • Subjects aged 19 years or older
  • Subjects who administered NURTEC® ODT 75 mg (Rimegepant sulfate) according to the approved label
  • Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Treatment and study plan

Rimegepant sulfate

Drug

ALL Who treated with Rimegepant sulfate

Primary outcomes

  1. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    All adverse events (AEs) Unit of Measure: Number of participants with AEs

  2. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Serious Adverse Events (SAEs) Unit of Measure : Number of participants with SAEs

  3. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Expected Adverse Events (Expected AEs) Unit of Measure : Number of participants with Expected AEs

  4. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Adverse Drug Reactions (ADRs) Unit of Measure : Number of participants with ADRs

  5. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Serious Adverse Drug Reactions (SADRs) Unit of Measure : Number of participants with SADRs

  6. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Unexpected Adverse Events (Unexpected AEs) Unit of Measure : Number of participants with Unexpected AEs

  7. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Expected Adverse Drug Reactions (Expected ADRs) Unit of Measure : Number of participants with Expected ADRs

  8. To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine.

    Time frame: 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate)

    Unexpected Adverse Drug Reactions (Unexpected ADRs) Unit of Measure : Number of participants with Unexpected ADRs

Secondary outcomes

  1. Acute Treatment Effectiveness : Pain Free at 2 Hours

    Time frame: 2 hours post-dose

    Percentage of subjects who are pain-free at 2 hours post-dose for the treatment of an acute migraine attack.

    Unit of Measure: Percentage of participants (%)

  2. Preventive Treatment Effectiveness : Change in Monthly Migraine Days (MMDs)

    Time frame: Baseline, 3 months, 6 months

    Mean change from baseline in the number of Monthly Migraine Days (MMDs). Unit of Measure: Days

  3. Preventive Treatment Effectiveness : Responder Rate (≥ 50% & ≥ 75%)

    Time frame: 3 months, 6 months

    Percentage of subjects who achieve a ≥50% & ≥ 75% reduction from baseline in MMDs.

    Unit of Measure: Percentage of participants (%)

  4. Preventive Treatment Effectiveness : MIDAS (Migraine Disability Assessment)

    Time frame: 3 months, 6 months

    Total score of the MIDAS questionnaire to assess headache-related disability. Unit of Measure: Score (points)

  5. Preventive Treatment Effectiveness : HIT-6 (Headache Impact Test-6)

    Time frame: 3 months, 6 months

    Total score of the HIT-6 questionnaire to measure the impact of headaches on daily life.

    Unit of Measure: Score (points

  6. Acute & Preventive Treatment Effectiveness

    Time frame: 24 weeks (at the completion of follow-up or at the time of treatment discontinuation/withdrawal)

    The percentage of subjects categorized as 'Improved' based on the investigator's clinical judgment and/or laboratory test results. Overall effectiveness is evaluated across four categories (Improved, Unchanged, Aggravated, Not assessed), with 'Improved' cases being used to calculate the final effectiveness rate.

    • Improved: Symptoms are deemed to be improved or maintained (including cases where the effect of a previous drug is maintained after switching to NURTEC® ODT).
    • Unchanged: Symptoms show no improvement compared to baseline, nor is there a maintenance effect.
    • Aggravated: Symptoms have worsened compared to baseline.
    • Not assessed: Effectiveness results are not available.

    Unit of Measure: Percentage of participants (%)

Study contacts

Contact information is provided by the study sponsor or research team.

Pfizer CT.gov Call Center

CONTACT

[email protected]

1-800-718-1021

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea.

Acronym: Rimegepant PMS

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Mar 27, 2026
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.